Rare cancers: A sea of opportunity

The Lancet Oncology

Volumn 17, Issue 2, 2016, Pages e52-e61

  Boyd, Niki ^a   Dancey, Janet E ^b   Gilks, C Blake ^a   Huntsman, David G ^a,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; IMATINIB; VEMURAFENIB;

ANAPLASTIC THYROID CANCER; BRAIN CANCER; CANCER CELL LINE; CANCER CLASSIFICATION; CANCER INCIDENCE; EYE MELANOMA; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; GENE MUTATION; GENETIC VARIABILITY; GIANT CELL TUMOR; GYNAECOLOGICAL SARCOMA; HISTOGENESIS; HUMAN; IMMUNOTHERAPY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTATIC ANAL CANCER; MOLECULAR GENETICS; NON SMALL CELL LUNG CANCER; PENIS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RARE DISEASE; REVIEW; SALIVARY GLAND CANCER; SARCOMA; SMALL BOWEL ADENOCARCINOMA; THYMOMA; CLASSIFICATION; GENETICS; GENOMICS; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS; PATHOLOGY; RARE DISEASES;

GENOMICS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; RARE DISEASES;

EID: 84959296158     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00386-1     Document Type: Review

References (106)

1. Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009, 96:20-26. the Rare Diseases Clinical Research Network.
2. Sokolowski E, Turina CB, Kikuchi K, Langenau DM, Keller C Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. Oncogene 2014, 33:1877-1889.
3. Song P, Gao J, Inagaki Y, Kokudo N, Tang W Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intract Rare Dis Res 2012, 1:3-9.
4. Gatta G, Capocaccia R, Trama A, Martínez-García C The burden of rare cancers in Europe. Adv Exp Med Biol 2010, 686:285-303. the RARECARE Working Group.
5. Munoz J, Kurzrock R Targeted therapy in rare cancers-adopting the orphans. Clin Oncol 2012, 9:631-642.
6. National Cancer Institute Epidemiology and Genetics Research. Synergizing epidemiologic research on rare cancers National Cancer, 2007 (accessed Dec 2, 2015). http://epi.grants.cancer.gov/events/rare-cancers/.
7. Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL The occurrence of rare cancers in U.S. adults, 1995-2004. Public Health Rep 2010, 125:28-43.
8. Pott P Cancer scroti 1775, Hawes, Clarke, Collins, London.
9. MacCarthy A, Birch JM, Draper GJ, et al. Retinoblastoma in Great Britain 1963-2002. Br J Ophthalmol 2009, 93:33-37.
10. Broaddus E, Topham A, Singh AD Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009, 93:21-23.
11. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986, 323:643-646.
12. Knudson AG Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823.
13. Anglesio MS, Wang Y, Yang W, et al. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J Pathol 2013, 229:400-409.
14. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 2012, 366:234-242.
15. Bogaerts J, Sydes MR, Keat N, et al. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer 2015, 51:271-281.
16. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014, 311:1998-2006.
17. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
18. Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.
19. International Cancer Genome Consortium. Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature 2010, 464:993-998.
20. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015, 373:726-736.
21. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
22. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003, 125:660-667.
23. Isozaki K, Hirota S Gain-of-function mutations of receptor tyrosine kinases in gastrointestinal stromal tumors. Curr Genomics 2006, 7:469-475.
24. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011, 364:2305-2315.
25. Jelinic P, Mueller JJ, Olvera N, et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet 2014, 46:424-426.
26. Ramos P, Karnezis AN, Craig DW, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet 2014, 46:427-429.
27. Witkowski L, Carrot-Zhang J, Albrecht S, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet 2014, 46:438-443.
28. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Nat Comp Cancer Net 2010, 8(suppl 2):S1-41. quiz S2-4.
29. Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005, 103:821-829.
30. Gittleman AM, Price AP, Coren C, Akhtar M, Donovan V, Katz DS Juvenile granulosa cell tumor. Clin Imaging 2003, 27:221-224.
31. Schumer ST, Cannistra SA Granulosa cell tumor of the ovary. J Clin Oncol 2003, 21:1180-1189.
32. Young RH Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol 2005, 18(suppl 2):S81-S98.
33. Shah SP, Köbel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009, 360:2719-2729.
34. Kommoss S, Anglesio MS, Mackenzie R, et al. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Mod Pathol 2013, 26:860-867.
35. Köbel M, Gilks CB, Huntsman DG Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res 2009, 69:9160-9162.
36. Al-Agha OM, Huwait HF, Chow C, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol 2011, 35:484-494.
37. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010, 363:1532-1543.
38. Virchow RLK Untersuchungen über die Entwickenlung des Schädelgrundes in gesunden und krakhaften Zustande und über den Einflus derselben auf Schädelform, Gesichtsbildung und gehirnbau 1857, G Zeimer, Berlin.
39. Oakley GJ, Fuhrer K, Seethala RR Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol 2008, 21:1461-1469.
40. Stacchiotti S, Sommer J Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 2015, 16:e71-e83. the Chordoma Global Consensus Group.
41. Sell S Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004, 51:1-28.
42. Choy E, MacConaill LE, Cote GM, et al. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. PLoS One 2014, 9:e101283.
43. Alholle A, Brini AT, Bauer J, et al. Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas. Epigenetics 2015, 10:213-220.
44. Askin FB, Rosai J, Sibley RK, Dehner LP, McAlister WH Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979, 43:2438-2451.
45. Fujii Y, Hongo T, Nakagawa Y, et al. Cell culture of small round cell tumor originating in the thoracopulmonary region. Evidence for derivation from a primitive pluripotent cell. Cancer 1989, 64:43-51.
46. Linnoila RI, Tsokos M, Triche TJ, Marangos PJ, Chandra RS Evidence for neural origin and PAS-positive variants of the malignant small cell tumor of thoracopulmonary region ("Askin tumor"). Am J Surg Pathol 1986, 10:124-133.
47. Contesso G, Llombart-Bosch A, Terrier P, et al. Does malignant small round cell tumor of the thoracopulmonary region (Askin tumor) constitute a clinicopathologic entity? An analysis of 30 cases with immunohistochemical and electron-microscopic support treated at the Institute Gustave Roussy. Cancer 1992, 69:1012-1020.
48. Whang-Peng J, Triche TJ, Knutsen T, et al. Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet Cytogenet 1986, 21:185-208.
49. Ali RH, Seidman JD, Luk M, Kalloger S, Gilks CB Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. Int J Gynecol Pathol 2012, 31:499-506.
50. Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2012, 25:625-636.
51. Howitt BE, Hanamornroongruang S, Lin DI, et al. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol 2015, 39:287-293.
52. McDivitt RW, Stewart FW Breast carcinoma in children. JAMA 1966, 195:388-390.
53. Rosen PP, Cranor ML Secretory carcinoma of the breast. Arch Pathol Lab Med 1991, 115:141-144.
54. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002, 2:367-376.
55. Knezevich SR, Garnett MJ, Pysher TJ, Beckwith JB, Grundy PE, Sorensen PH ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 1998, 58:5046-5048.
56. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998, 18:184-187.
57. Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010, 34:599-608.
58. Kralik JM, Kranewitter W, Boesmueller H, et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol 2011, 6:19.
59. Makretsov N, He M, Hayes M, et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 2004, 40:152-157.
60. Edmondson HA Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 1956, 91:168-186.
61. Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014, 343:1010-1014.
62. Azzoli CG, Baker S, Temin S, et al., the American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
63. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625. NSCLC Meta-Analyses Collaborative Group.
64. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009, 14:253-263.
65. Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti G Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2009, 2:s851.
66. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
67. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
68. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
69. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
70. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
71. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
72. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
73. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
74. Li T, Kung HJ, Mack PC, Gandara DR Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013, 31:1039-1049.
75. Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ Polymerase e (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 2015, 121:386-394.
76. Church DN, Briggs SE, Palles C, et al., the NSECG Collaborators. DNA polymerase e and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet 2013, 22:2820-2828.
77. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2015, 107:402.
78. Meng B, Hoang LN, McIntyre JB, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 2014, 134:15-19.
79. Hussein YR, Weigelt B, Levine DA, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol 2015, 28:505-514.
80. Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015, 113:299-310.
81. Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 2009, 325:965.
82. Karnezis AN, Wang Y, Ramos P, et al. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcemic type. J Pathol 2015, published online Sept 10. 10.1002/path.4633.
83. Oike T, Ogiwara H, Tominaga Y, et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res 2013, 73:5508-5518.
84. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
85. Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015, 33:4032-4038.
86. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012, 2:227-235.
87. Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013, 19:657-667.
88. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
89. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
90. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
91. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
92. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233-5239.
93. Hinrichs CS, Rosenberg SA Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014, 257:56-71.
94. Linnemann C, van Buuren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015, 21:81-85.
95. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA4 blockade in melanoma. N Engl J Med 2014, 371:2189-2199.
96. Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515:572-576.
97. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471:377-381.
98. Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515:572-576.
99. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
100. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010, 363:1727-1733.
101. Keat N, Law K, McConnell A, et al. International Rare Cancers Initiative (IRCI). Ecancermedicalscience 2013, 7:ed20.
102. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006, 103:690-695.
103. Cheng HP, Clarkson PW, Gao D, Pacheco M, Wang Y, Nielsen TO Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma 2010, 2010:174528.
104. Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012, 118:1649-1655.
105. Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 2015, 373:428-437.
106. Billingham L, Malottki K, Steven N Research methods to change clinical practice for patients with rare cancers. Lancet Oncol 2016, 17:e70-e80.